Neoadjuvant Botensilimab/Balstilimab for localized mismatch repair proficient and deficient colon cancer: Results of the NEST phase 2 clinical trial
Manish A. Shah, Erika Hissong, Mehraneh Dorna Jafari, Pashtoon Murtaza Kasi et autres
PURPOSE: Effective immunotherapy for mismatch repair proficient colorectal cancer (CRC) is lacking. We examined the safety and efficacy of the novel next-generation immune activator/Fc-enhanced CTLA-4 inhibitor botensilimab (BOT) plus PD-1 inhibitor balstilimab (BAL) in the neoadjuvant setting for patients with resectable CRC. …
us, qa (code pays fourni par la source)
0 citations
Clinical Cancer Research